Repligen (RGEN) traded lower Thursday, April 16, 2026, down 3.28% to $128.51. The decline looks more like a sentiment/positioning move than a single-company headline: the stock has been sensitive to its 2026 outlook since management issued guidance on Feb. 24, 2026, and investors are also repositioning ahead of the next quarterly report window.

The overhang remains Repligen’s 2026 guidance framework released with fourth-quarter and full-year 2025 results on Feb. 24, 2026, which highlighted the company’s expectations for 2026 performance and has been a focal point for investors since. In the weeks that followed, at least one analyst reduced their price target—Evercore ISI cut its target to $140 while keeping an Outperform rating on April 6, 2026—reinforcing a more cautious near-term setup despite longer-term optimism.

The next major catalyst is Repligen’s upcoming first-quarter earnings report, which multiple market calendars place in late April 2026 (date/time varies by source), increasing the odds of volatility as investors trade around expectations. Traders will be watching for updates on demand trends across bioprocessing end markets and any changes to the company’s 2026 revenue and margin assumptions.